1. What Is the Menopause Market?
The Menopause Market covers the pharmacological treatments for the bothersome menopausal symptoms that the cessation of the ovarian oestrogen and progesterone production creates. The symptoms include the vasomotor symptoms of the hot flushes and the night sweats affecting 75 percent of women. The symptoms also include the genitourinary syndrome of menopause and the sleep disturbance and the mood changes. Non-hormonal menopause treatment has been transformed by the fezolinetant oestrogen-free neurokinin 3 receptor antagonist that the FDA approved in May 2023 for the moderate-to-severe vasomotor symptoms. The drug blocks the hypothalamic NKB-NK3R pathway that the oestrogen deficiency activates to trigger the hot flush. The drug works without the oestrogen exposure that HRT provides. The menopause market is advancing with the elinzanetant selective NK1 and NK3 receptor dual antagonist that the OASIS Phase III programme is developing for the vasomotor symptoms.
2. Menopause Market Size & Forecast
3. Emerging Technologies
- Fezolinetant Veozah NK3 receptor antagonist SKYLIGHT 1 and 2 Phase III demonstrated the 58 and 61 percent reduction in the weekly hot flush frequency versus 26 and 23 percent placebo at week 12. The trial enrolled the postmenopausal women with the 7 or more moderate-to-severe hot flushes per day. The trial established the first non-hormonal oestrogen-free pharmacological treatment approved for the vasomotor symptoms.
- Neurokinin B NK3 receptor pathway in the thermoregulation involves the hypothalamic KNDy neurons that release the kisspeptin, neurokinin B, and dynorphin to regulate the GnRH pulse. The pathway provides the mechanistic explanation for the hot flush from the oestrogen deficiency. The deficiency removes the oestrogen inhibition of the KNDy neuron activity and allows the NKB-NK3R cascade to activate the thermoregulatory centre.
- SSNRIs venlafaxine and desvenlafaxine and SSRI paroxetine Brisdelle treat the vasomotor symptoms in the HRT-contraindicated breast cancer survivor and the woman who declines HRT. The drugs achieve the 50 to 60 percent hot flush frequency reduction. The reduction occurs at the non-antidepressant dose.
- Stellate ganglion block anaesthetic injection into the C6 stellate ganglion reduces the sympathetic efferent traffic to the thermoregulatory hypothalamus. The block achieves the 60 percent hot flush frequency reduction in the Phase II trial. The block suits the breast cancer survivor with the severe HRT-contraindicated vasomotor symptoms.
Similar technologies are also transforming adjacent markets. Learn more in our Postpartum Depression Market.
4. Key Market Opportunity
A material opportunity in the Menopause market is centered on fezolinetant adoption in HRT-averse women and HRT-contraindicated patients, where the non-hormonal vasomotor symptom mechanism addresses a large segment without HRT access. Astellas Pharma capturing fezolinetant commercial expansion represents this substantial opportunity. Additional momentum comes from additional NK3 antagonist programme expansion. As fezolinetant adoption proceeds and additional non-hormonal programmes advance, the addressable opportunity is growing from HRT-dominant menopause treatment toward substantial non-hormonal vasomotor therapy.
5. Top Companies in the Menopause Market
The following organisations hold leading positions in the Menopause Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Astellas Pharma
- Bayer
- Pfizer
- Mithra Pharmaceuticals
- TherapeuticsMD
- Theramex
- Novo Nordisk
- Sanofi
- AbbVie
- Mayne Pharma
- Viatris
- Lupin
6. Market Segmentation
The Menopause Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Symptom Target | Vasomotor Genitourinary Sleep Mood |
| By Treatment | HRT Non-Hormonal NK3 Antagonist SERM Vaginal Estrogen |
| By Drug | Fezolinetant Ospemifene Prasterone |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Menopause Market trajectory over the forecast period:
Fezolinetant Veozah NK3 Receptor Antagonist SKYLIGHT 1 and 2 58 to 61 Percent Hot Flush Frequency Reduction Versus 23 to 26 Percent Placebo at Week 12 Has Established the First Non-Hormonal Oestrogen-Free Pharmacological Vasomotor Symptom Treatment for the HRT-Declined or Contraindicated Patient.Astellas Pharma's fezolinetant Veozah demonstrated 9.3-point reduction in moderate-to-severe hot flush frequency versus 3.3 for placebo in SKYLIGHT 1 and 2, and the non-hormonal mechanism makes Veozah appropriate for women with breast cancer, hormone-receptor-positive conditions, or cardiovascular risks where oestrogen contraindications have historically left hot-flush management unaddressed by prescription therapy. The NK3R mechanism suppresses the kisspeptin-neurokinin-dynorphin neuron activity in the hypothalamic thermoregulatory centre that is normally inhibited by oestrogen and becomes hyperactive in menopause, producing the heat-dissipation response experienced as hot flushes through a pathway completely independent of oestrogen supplementation. The real-world prescribing uptake of fezolinetant has been strongest in women with breast cancer-related premature menopause from chemotherapy and aromatase inhibitor therapy, where the unmet need is most acute and where physicians actively sought a safe non-hormonal prescription alternative to venlafaxine off-label use.
KNDy Neuron NKB-NK3R Thermoregulation Pathway Activated by Oestrogen Deficiency Removing the Inhibitory Oestrogen Restraint Has Established the Mechanistic Basis for the Fezolinetant NK3 Antagonism That Targets the Hot Flush Trigger at the Hypothalamic Thermoregulatory Centre.The NAMS 2022 hormone therapy position statement explicitly concluded that the cardiovascular, stroke, and breast cancer risks reported in the Women's Health Initiative were specific to the older age and higher cardiovascular risk of WHI participants and do not apply to standard hormone therapy use in healthy perimenopausal women aged 50-60. The reversal of post-WHI prescribing practice has required systematic prescriber education by NAMS, British Menopause Society, and European Menopause and Andropause Society that the WHI findings were misapplied to an entirely different population than the 63-year-average-age, overweight, hypertensive WHI participants. Prescribing rates for systemic HRT in women aged 50-60 have increased approximately 20-30% in the US and UK following updated guideline communication, and the primary growth driver is the large population of perimenopausal women with bothersome vasomotor symptoms who had declined or had HRT discontinued in the immediate post-WHI decade.
Stellate Ganglion Block Anaesthetic Injection 60 Percent Phase II Hot Flush Frequency Reduction in Breast Cancer Survivors With HRT-Contraindicated Severe Vasomotor Symptoms Has Established the Non-Pharmacological Sympathetic Efferent Interruption as the Procedure Option for the Highest-Risk Patient.The E3N-EPIC cohort study demonstrated no increased breast cancer risk with transdermal oestradiol plus progesterone versus 1.69-fold risk with oral oestrogen plus synthetic progestogen, and the NHS Choices guidance and BMS position statement now recommend transdermal E2 plus micronised progesterone as the preferred HRT formulation for women without contraindications to this route. The transdermal delivery bypasses hepatic first-pass metabolism that generates the clotting factors and CRP elevation associated with oral conjugated oestrogens and increased venous thromboembolism risk, providing a route-specific safety advantage that supports transdermal prescription in women with borderline VTE risk who can tolerate HRT with appropriate route selection. Estradiol gel and patch prescribing from AbbVie, Noven, and Besins Healthcare has grown substantially faster than oral conjugated oestrogen in the post-2020 period as prescribers and patients incorporate route-of-administration safety data into informed HRT decision-making.
For related market intelligence, see the Hrt Market.
8. Segmental Analysis
By symptom target, the vasomotor symptom segment dominated the Menopause Market in 2025, as hormonal and Astellas Pharma's Veozah non-hormonal therapies anchored treatment of hot flushes and night sweats, generating the largest share of menopausal treatment revenue.
By treatment, the non-hormonal therapy segment is projected to register the highest growth rate through 2034, as Astellas Pharma's fezolinetant and follow-on NK3-receptor antagonists expand into the large population of hormone-averse women and those with contraindications to oestrogen.
9. Regional Analysis
Regional demand patterns across the Menopause Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Menopause Market in 2025, accounting for approximately 45% of global revenue, attributed to US premium pricing for fezolinetant, ospemifene, and prasterone and the large postmenopausal patient population. Moreover, fezolinetant non-hormonal adoption is most advanced in the US following approval. In addition, GSM-targeted therapy prescribing is established. Regional dominance is due to this combination of pricing environment and non-hormonal therapy adoption.
Highest CAGR Region
Europe is projected to register the highest CAGR in the Menopause Market through 2034, driven by expanding fezolinetant access across European healthcare systems and the large European menopausal patient population with growing menopause symptom awareness. The region is also witnessing non-hormonal menopause therapy adoption growing. Moreover, menopause clinic infrastructure is expanding. The combination of these demand drivers and access expansion positions Europe for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Menopause Market was valued at USD 4.81 Bn in 2025 and is projected to reach USD 9.14 Bn by 2034, growing at a CAGR of 7.4% over the 2026–2034 forecast period.
The Menopause Market is projected to grow at a CAGR of 7.4% from 2026 to 2034.
North America dominated the Menopause Market in 2025, accounting for approximately 45% of global revenue, attributed to US premium pricing for fezolinetant, ospemifene, and prasterone and the large postmenopausal patient population.
The leading companies in the Menopause Market include Astellas Pharma, Bayer, Pfizer, Mithra Pharmaceuticals, TherapeuticsMD, Theramex, Novo Nordisk, Sanofi, AbbVie, Mayne Pharma, Viatris, Lupin.
Fezolinetant veozah nk3 receptor antagonist skylight 1 and 2 58 to 61 percent hot flush frequency reduction versus 23 to 26 percent placebo at week 12 has established the first non-hormonal oestrogen-free pharmacological vasomotor symptom treatment for the hrt-declined or contraindicated patient.
By symptom target, the vasomotor symptom segment dominated the Menopause Market in 2025, as hormonal and Astellas Pharma's Veozah non-hormonal therapies anchored treatment of hot flushes and night sweats, generating the largest share of menopausal treatment revenue.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.